Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

	ne of entity		ABN/ARSN			
Sig	ma Pharmaceuticals Limited	15 088 417 403				
We	(the entity) give ASX the following	information.				
Inf	Cormation about buy-back					
1	Type of buy-back	On-market buy-back				
2	Date Appendix 3C was given to ASX					
		2015)				
	tal of all shares/units bought ve been received, before, and	back, or in relation to	which acceptances Previous day			
	9	back, or in relation to on, previous day	-			

Before previous day	Previous day

5 If buy-back is an on-market buy-

Highest \$0.8700	price	paid:	Highest price paid: \$0.7900		
, , , , ,			Lowest price paid:		
Lowest \$0.5600	price	paid:	\$0.7825		
φυ.σσσσ	Hig		Highest price allowed		
			under rule 7.33:		
			\$0.8382		

How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

7,033,932		

Date: 16 December 2015

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Print name:

(Director/Company secretary)

Director Company secretary

JEFF SELLS

== == == == ==